Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: BRCA1 Gene Mutation|BRCA2 Gene Mutation|Locally Advanced Solid Neoplasm|Metastatic Malignant Solid Neoplasm|POLD1 Gene Mutation|POLE Gene Mutation|Recurrent Malignant Solid Neoplasm|Recurrent Ovarian Carcinoma|Stage III Breast Cancer AJCC v7|Stage III Ovarian Cancer AJCC v8|Stage IIIA Breast Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIB Breast Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIC Breast Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v8|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8
Interventions: OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pembrolizumab
Sponsor: Rutgers, The State University of New Jersey
Collaborators: National Cancer Institute (NCI)